Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>Events>This Event
  Events - October 2013

SMi - Diabetes: Secondary Complications, Regulation and Innovation

01 Oct 2013 - 02 Oct 2013 - London, UK

Bookmark and Share

Join your peers at the only conference dedicated to the leading causes of mortality and morbidity in diabetes, this autumn, in London. Our distinguished faculty unite the fields of pharmacology, nanotechnology and clinical medicine to target atherosclerosis, endothelial inflammation and end-stage renal disease. 

SMi's unique program brings together the latest research from those at the forefront of attenuating the complications arising from hyperglycaemia, dyslipidaemia, and angiopathy.  

“This conference is an excellent one stop shop to up-skill on current issues in diabetes therapy. I’m happy to chair what will no doubt be a very stimulating session.” – Phil Ambery, Medical Director, GlaxoSmithKline

Key Reasons to Attend:

Receive clinical updates on novel GLP1 receptor agonists, and SLGT2 and DPP-4 inhibitors

Utilise biomarkers and imaging for the development of novel therapies for diabetes

Discuss new therapeutic targets to reduce hypertension, hyperkalaemia and endothelial inflammation in diabetes

Remain abreast of new EU and FDA guidelines on clinical trials on risk-benefit assessment

Capitalise on the effects of targeting RAAS, CCN2 and CCN3 inhibitors

Review clinical results from the DEMAND study

Key Speakers Include: 

James F. List, Vice President and Full Development Lead, Dapagliflozin, Bristol-Myers Squibb

John Wilding, Professor of Medicine & Honorary Consultant Physician, Head of Department of Obesity and Endocrinology, University of Liverpool Hospital

Martin Siman, Director, Design and Interpretation Centre of Excellence, AstraZeneca

Philip Ambery, Director, Clinical Development, GlaxoSmithKline

Sandra Souza, Team Lead, Molecular Biomarkers, PPDM , Merck Sharp & Dohme 

Diabetes: Secondary Complications, Regulation and Innovation, promises to be a unique platform for networking, problem solving and learning from timely case studies. This really is a unique event not to be missed.

Book online at

Contact John Collins: Email: Tel: +44 (0)207 827 6734

Further information
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos